AZD-2858 manufacturers and suppliers in india

AZD-2858

Properties

Density: 1.408±0.06 g/cm3(Predicted)

storage temp.: Store at -20° C

solubility: DMSO:8.0(Max Conc. mg/mL);17.64(Max Conc. mM)

form: A crystalline solid

pka: 7.17±0.70(Predicted)

color: Green to khaki

Safety Information

Symbol(GHS): GHS08,GHS06

Signal word: Danger

Hazard statements: H301-H372-H341

Precautionary statements: P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P270-P314-P501-P201-P202-P281-P308+P313-P405-P501

Use

In rats, oral AZD2858 treatment causes a dose-dependent increase in trabecular bone mass compared to control after a two-week treatment with a maximum effect at a dose of 20 mg/kg once daily (total BMC: 172% of control). A small but significant effect is also seen at cortical sites (total BMC: 111% of control). AZD285 treatment (30 mol/kg) on rats daily for up to 3 weeks shows an increase in both mineral density (of 28% at 2 weeks and 38% at 3 weeks) and mineral content (of 81% at 2 weeks and 93% at 3 weeks) in the calluses. AZD285 treatment makes the fractures heals more rapidly, with a bony callus without an obvious endochondral component. AZD2858 produces time-dependent changes in serum bone turnover biomarkers and increases bone mass over 28 days exposure in rats. After 7 days, AZD2858 increases the bone formation biomarker P1NP, and reduces the resorption biomarker TRAcP-5b, indicating increased bone anabolism and reduced resorption in rats.